The largest database of trusted experimental protocols

Edta 0.02 solution

Manufactured by Merck Group
Sourced in Poland

EDTA 0.02% solution is a laboratory reagent that contains a 0.02% concentration of the chelating agent ethylenediaminetetraacetic acid (EDTA). EDTA is commonly used in various analytical and experimental procedures to sequester metal ions, regulate pH, and maintain the stability of samples.

Automatically generated - may contain errors

2 protocols using edta 0.02 solution

1

Gastric Adenocarcinoma Cell Lines Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Two gastric adenocarcinoma cell lines were used: the EPG85-257 P – sensitive and EPG85-257 RDB – daunorubicin-resistant cell line. Human gastric cancer cells were obtained as a kind gift from Prof. Herman Lage. The EPG85-257 RDB cell line reveals the overexpression of MDR1 and the resistance to daunorubicin [37 (link)]. Both cell lines were cultured in Leibovitz L-15 medium (Sigma-Aldrich, Poznan, Poland) supplemented by 10% fetal bovine serum (FBS, Lonza, Poland), 1% antibiotics (penicillin/streptomycin, Sigma-Aldrich, Poznan, Poland), 1 mM ultraglutamine (Sigma-Aldrich, Poznan, Poland), 6.25 mg/L fetuin (Sigma-Aldrich, Poznan, Poland), 2.5 mg/mL transferrin (Sigma-Aldrich, Poznan, Poland), 0.5 g/L glucose, 1.1 g/L NaHCO3, and 1% minimal essential vitamins (Mem-Vit, Sigma-Aldrich, Poznan, Poland). Cell cultures were cultured as a monolayer on a 25 and 75 cm2 plastic flask (Sarstedt, Germany) maintained in a humidified atmosphere at 37 °C and 5% CO2, and detached for the experiments by trypsinization (trypsin 0.025% and EDTA 0.02% solution, Sigma-Aldrich, Poznan, Poland). Cells were passed every 2–3 days and a day before the experiment.
+ Open protocol
+ Expand
2

Culturing Doxorubicin-Resistant Breast Cancer and Melanoma Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
The studies were performed in vitro on human breast adenocarcinoma cell line doxorubicin-resistant type (MCF-7/DX), obtained from the Department of Tumor Biology, Comprehensive Cancer Center, Maria Sklodowska-Curie Memorial Institute in Gliwice (Poland), human amelanotic melanoma cells (C32) purchased in ATCC®, MC38 murine colon adenocarcinoma cells were adapted to in vitro conditions in Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences (Wroclaw, Poland)33 (link). MCF-7/DX and C32 cells were grown in DMEM (Sigma, Poland), supplemented with 10% fetal bovine serum (Lonza BioWhittaker, Switzerland) and penicillin/streptomycin (Sigma, Poland). MC38 cells were maintained RPMI (Sigma, Poland) supplemented with 5% fetal bovine serum (FBS, Lonza BioWhittaker, Switzerland), 1% penicillin/streptomycin (Sigma, Poland), 0.5% sodium pyruvate (Sigma-Aldrich) and 50 µmol/L 2-mercaptoethanol (Sigma-Aldrich). Cell cultures were cultivated as a monolayer on a plastic flask 25 and 75 cm2 (Nunc, Denmark), maintained in a humidified atmosphere at 37 °C and 5% CO2. and detached for the experiments by trypsinization (trypsin 0.025% and EDTA 0.02% solution, Sigma, Poland). Cells were passed every 2–3 days and a day before the experiment.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!